Xilio Therapeutics, Inc. Stock Price, News & Analysis

Xilio Therapeutics (Nasdaq: XLO) announced on Oct 2, 2025 that effective Oct 1, 2025 it granted non‑qualified stock options to purchase 26,000 shares to three new employees under its 2022 Inducement Stock Incentive Plan.

The options have an exercise price of $0.8326 (equal to the closing price on Oct 1, 2025), a 10‑year term, and vest 25% after 1 year with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. Grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the plan and option agreement terms.

Xilio Therapeutics (NASDAQ:XLO) has initiated Phase 2 patient dosing for efarindodekin alfa (XTX301), a tumor-activated IL-12 therapy for advanced solid tumors. The company has also achieved a $17.5 million development milestone under its exclusive license agreement with Gilead Sciences.

Phase 1 data showed promising results with two partial responses in late-line patients and a generally well-tolerated safety profile. The company has selected the recommended Phase 2 dose (RP2D) based on these encouraging results. The therapy demonstrated sustained interferon gamma signaling without tachyphylaxis throughout treatment cycles.

Financially, Xilio reported cash and cash equivalents of $121.6 million as of June 30, 2025. With the additional milestone payment, the company expects to fund operations into Q1 2027.

Xilio Therapeutics (NASDAQ:XLO) reported Q2 2025 financial results and pipeline updates. The company's lead candidate vilastobart showed promising Phase 2 data with a 26% objective response rate in metastatic MSS colorectal cancer patients without liver metastases. The therapy demonstrated deep, durable responses and a differentiated safety profile.

Financial highlights include $121.6 million in cash and cash equivalents, a net loss of $15.8 million, and revenue of $8.1 million. The company completed a follow-on offering raising $50.0 million in initial gross proceeds, with potential for additional $100.0 million from warrant exercises.

Xilio expects to nominate development candidates for its masked T cell engager programs in H2 2025 and projects cash runway through Q3 2026.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted inducement stock options to two new employees. The grants include options to purchase 134,000 shares of common stock at an exercise price of $0.65 per share, matching the closing price on August 1, 2025.

The stock options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting in 36 monthly installments. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to two new employees effective July 1, 2025. The inducement grants include options to purchase 10,700 shares of common stock at an exercise price of $0.693 per share.

The stock options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (Nasdaq: XLO) has appointed Akintunde (Tunde) Bello, Ph.D., to its board of directors. Dr. Bello brings over 25 years of oncology drug development experience, particularly in translational medicine and clinical pharmacology. He recently retired as senior vice president at Bristol Myers Squibb, where he led clinical pharmacology and pharmacometrics. His expertise spans complex biologics and immunotherapies, including anti-CTLA-4, PD-1 checkpoint inhibitors, and T cell engagers. The appointment comes as Xilio advances XTX501, its masked PD-1/IL-2 bi-specific program, along with other bi-specific and tri-specific masked T cell engager programs. Dr. Bello previously held leadership roles at Pfizer, overseeing clinical pharmacology for late-stage oncology development programs.

Xilio Therapeutics (XLO) has completed a public offering raising initial gross proceeds of $50.0 million through pre-funded warrants and common stock warrants. The offering was co-led by Coastlands Capital and Frazier Life Sciences, with participation from Gilead Sciences, Logos Capital, Samsara BioCapital, and other investors. The company issued 66,676,000 pre-funded warrants with accompanying Series A, B, and C warrants. If all Series B and C warrants are exercised at $0.75 per share, Xilio could receive up to an additional $100 million by end of 2026, potentially reaching total gross proceeds of $150 million. The company can cancel warrants proportionally to non-dilutive capital received. Proceeds will support product candidate development and general corporate purposes.

Xilio Therapeutics (XLO) has granted stock options to five new employees as part of their employment inducement package. The grants, effective June 1, 2025, include options to purchase 181,300 shares of common stock at an exercise price of $1.07 per share, matching the company's closing price on May 30, 2025. The options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (XLO) has priced a $50.0 million public offering of pre-funded warrants and multiple series of warrants. The offering includes pre-funded warrants to purchase 66,676,000 shares, along with Series A, B, and C warrants, each to purchase the same number of shares. The combined offering price is $0.7499 per unit. The pre-funded warrants have a $0.0001 exercise price, while Series A, B, and C warrants have a $0.75 exercise price with different exercise periods and conditions. If all Series B and C warrants are exercised in cash, the company could receive additional gross proceeds of up to $100.0 million. The proceeds will be used for product candidate development and general corporate purposes. Leerink Partners is serving as the sole bookrunner, with the offering expected to close around June 5, 2025.